The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Coffee Consumption, Gender, and Parkinson’s Disease Mortality in the Cancer Prevention Study II Cohort: The Modifying Effects of Estrogen
Abstract
Caffeine consumption is associated with a reduced risk of Parkinson's disease in men but not in women. This gender difference may be due to an interaction between caffeine and use of postmenopausal estrogens. The authors prospectively assessed the relation between coffee consumption and Parkinson's disease mortality among participants in the Cancer Prevention Study II, a cohort of over 1 million people enrolled in 1982. Causes of deaths were ascertained through death certificates from January 1, 1989, through 1998. Parkinson's disease was listed as a cause of death in 909 men and 340 women. After adjustment for age, smoking, and alcohol intake, coffee consumption was inversely associated with Parkinson's disease mortality in men (p(trend) = 0.01) but not in women (p = 0.6). In women, this association was dependent on postmenopausal estrogen use; the relative risk for women drinking 4 or more cups (600 ml) of coffee per day compared with nondrinkers was 0.47 (95% confidence interval: 0.27, 0.80; p = 0.006) among never users and 1.31 (95% confidence interval: 0.75, 2.30; p = 0.34) among users. These results suggest that caffeine reduces the risk of Parkinson's disease but that this hypothetical beneficial effect may be prevented by use of estrogen replacement therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An inverse association between coffee consumption and PD risk has been found in several epidemiological studies [110,121,122,123].”
From Effect of Caffeine Consumption on the Risk for Neurological and Psychiatric Disorders: Sex Differences in Human (2020) · cites this paper as [122]
Citations
Cites
Tanner, C. M., Ottman, R., Goldman, S. M., Ellenberg, J., Chan, P., Mayeux, R. P., & Langston, J. W. (1999) · JAMA · doi:10.1001/jama.281.4.341 · Cited by 876
A meta‐analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease
Hernán, M. A., Takkouche, B., Caamaño‐Isorna, F., & Gestal‐Otero, J. J. (2002) · Annals of Neurology · doi:10.1002/ana.10277 · Cited by 818
Association of coffee and caffeine intake with the risk of Parkinson disease
Ross, G. W. (2000) · JAMA · doi:10.1001/jama.283.20.2674 · Cited by 778
Prospective Study of Caffeine Consumption and Risk of Parkinson’s Disease in Men and Women
Ascherio, A., Zhang, S. M., Hernán, M. A., Kawachi, I., Colditz, G. A., Speizer, F. E., & Willett, W. C. (2001) · Annals of Neurology · doi:10.1002/ana.1052 · Cited by 677
Self-citationAdenosine, Adenosine Receptors and the Actions of Caffeine
Fredholm, B. B. (1995) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1995.tb00111.x · Cited by 597
Calle, E. E., & Terrell, D. D. (1993) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116664 · Cited by 342
Neuroprotective agents for clinical trials in Parkinson’s disease
Ravina, B. M., Fagan, S. C., Hart, R. G., Hovinga, C. A., Murphy, D. D., Dawson, T. M., & Marler, J. R. (2003) · Neurology · doi:10.1212/01.wnl.0000058760.13152.1a · Cited by 262
Caffeine, postmenopausal estrogen, and risk of Parkinson’s disease
Ascherio, A., Chen, H., Schwarzschild, M. A., Zhang, S. M., Colditz, G. A., & Speizer, F. E. (2003) · Neurology · doi:10.1212/01.wnl.0000046523.05125.87 · Cited by 237
Smoking, alcohol, and coffee consumption preceding Parkinson’s disease: A case-control study
Benedetti, M. D., Bower, J. H., Maraganore, D. M., McDonnell, S. K., Peterson, B. J., Ahlskog, J. E., Schaid, D. J., & Rocca, W. A. (2000) · Neurology · doi:10.1212/wnl.55.9.1350 · Cited by 234
Benedetti, M. D., Maraganore, D. M., Bower, J. H., McDonnell, S. K., Peterson, B. J., Ahlskog, J. E., Schaid, D. J., & Rocca, W. A. (2001) · Movement Disorders · doi:10.1002/mds.1170 · Cited by 224
Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations
Tsang, K., Ho, S.-L., & Lo, S. K. (2000) · Neurology · doi:10.1212/wnl.54.12.2292 · Cited by 204
Caffeinated clues and the promise of adenosine A2Aantagonists in PD
Schwarzschild, M. A., Chen, J., & Ascherio, A. (2002) · Neurology · doi:10.1212/wnl.58.8.1154 · Cited by 162
Lelo, A., Miners, J. O., Robson, R. A., & Birkett, D. (1986) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1986.10 · Cited by 159
Postmenopausal estrogen use and Parkinson's disease with and without dementia
Marder, K. S., Tang, M. X., Alfaro, B., Mejía, H., Cote, L. J., Jacobs, D. M., Stern, Y., Sano, M. C., & Mayeux, R. P. (1998) · Neurology · doi:10.1212/wnl.50.4.1141 · Cited by 153
Inhibition of Caffeine Metabolism by Estrogen Replacement Therapy in Postmenopausal Women
Pollock, B. G., Wylie, M. E., STACK, J. A., Sorisio, D. A., Thompson, D. S., Kirshner, M. A., Folan, M., & Condifer, K. A. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/00912709922008560 · Cited by 121
Is there a connection between estrogen and Parkinson’s disease?
Shulman, L. M. (2002) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(02)00014-7 · Cited by 118
Mortality in patients with Parkinson's disease
Wermuth, L., Stenager, E., Stenager, E., & Boldsen, J. L. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1995.tb00466.x · Cited by 84
Estrogen and Parkinson s disease
Kompoliti, K. (2003) · Frontiers in bioscience · doi:10.2741/1070 · Cited by 50
Epidemiological research at the American Cancer Society.
Thun, M. J., Calle, E. E., Rodríguez, C., & Wingo, P. A. (2000) · PubMed · Cited by 47
Validity of mortality data for Parkinson's disease.
Phillips, N. J., Reay, J., & Martyn, C. N. (1999) · Journal of Epidemiology & Community Health · doi:10.1136/jech.53.9.587 · Cited by 39
Flagged first, then by citations
Cited by
Sorted by citations
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
Lees, A. J., Hardy, J., & Revesz, T. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60492-x · Cited by 1,956
The epidemiology of Parkinson's disease: risk factors and prevention
Ascherio, A., & Schwarzschild, M. A. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30230-7 · Cited by 1,930
Epidemiology and etiology of Parkinson's disease: a review of the evidence
Wirdefeldt, K., Adami, H.-O., Cole, P., Trichopoulos, D., & Mandel, J. (2011) · European Journal of Epidemiology · doi:10.1007/s10654-011-9581-6 · Cited by 1,199
Coffee and Health: A Review of Recent Human Research
Higdon, J. V., & Frei, B. (2006) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408390500400009 · Cited by 1,090
Metadata
- Authors
- Ascherio, A.
- Affiliations
- Harvard University (US)
- Corresponding author
- Ascherio, A.
- ORCID
- Ascherio, A.
- Venue
- American Journal of Epidemiology
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-11-15
- Volume
- 160
- Issue
- 10
- Pages
- 977-984
- ISSN
- 0002-9262 (ISSN-L)
- OpenAlex
- W2113279750
- Cited by
- 232
- References
- 20
- Citations by year
- 2025: 6 · 2024: 6 · 2023: 8 · 2022: 13 · 2021: 7 · 2020: 6 · 2019: 12 · 2018: 15 · 2017: 16 · 2016: 9 · 2015: 14 · 2014: 18 · 2013: 14 · 2012: 9
- FWCI
- 7.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Epidemiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Michael J. Fox Foundation for Parkinson's Research
- Kinetics Foundation
- National Institutes of Health
- National Institute of Neurological Disorders and Stroke (NS045893-01, R01NS045893)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Coffee research and impacts
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- coffee consumption, caffeine, estrogen replacement therapy, postmenopausal hormone use, sex differences, Cancer Prevention Study II
- MeSH terms
- Aged, Coffee, Drug Interactions, Estrogens, Female, Humans, Male, Middle Aged, Neoplasms, Parity, Parkinson Disease, Surveys and Questionnaires, Risk, Sex Factors, Smoking, United States, Confidence Intervals
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
